Evidence linking omega-3 fatty acid deficiencies to mood disorders was demonstrated in two recent studies, with diminished EPA and DHA levels being suggested as modifiable risk factors or prodromal biomarkers for depressive illness in adolescents.[1,2]
Dr Brandon Brock joins Andrew to give our listeners some insight into the many opportunities that taking an integrative approach can have in helping those living with PTSD.
This study shows that magnesium can reduce depressive symptoms in those with hypomagnesaemia, even when using a less absorbable form.
On analysing the scientific basis for the efficacy of S-Adenosylmethionine (SAMe), a recent comprehensive review shows the beneficial effect of supplemental SAMe as a potential alternative to or adjunctive therapy for use with antidepressants.
S-adenosylmethionine (SAMe) is integral to cellular metabolism and as the major methyl donor in the body. SAMe is involved in the methylation of a diverse range of compounds including phospholipids, DNA, RNA, proteins and neurotransmitters. It is also involved in two other important pathways – transsulfuration which produces glutathione, and aminopropylation which synthesises polyamines.
Functional pathology testing for neurotransmitters may offer some insights for practitioners who are treating depression, anxiety, insomnia and chronic pain. Beth Bundy talks testing benefits and pitfalls.
Improvements in brain white matter may be a good predictive measure of omega 3 benefit in depression.
Evidence shows that certain complementary medicines hold great value in the treatment of mood disorders. We take a look at some of the recent research.